diff --git a/src/contents/description.tsx b/src/contents/description.tsx
index 0d3c8a5f1bcf09b02f1acada0b27b6831bef4154..628f4dcf462f2c5b95c08a51585d90bf509bbd58 100644
--- a/src/contents/description.tsx
+++ b/src/contents/description.tsx
@@ -104,11 +104,16 @@ export function Description() {
                 alt="methods"
                 className="responsive-img"
               />
-                 <p>1.Osmotic laxatives:Non-absorbable disaccharides, lactulose and sugar alcohols, are recommended as first-line treatment for HE. Lactulose is a laxative that has a negligible effect on the composition or function of the gut microbiota and may reduce ammonia production and absorption in the gut and increase intestinal excretion by increasing intestinal transport as well as acidification of the intestinal environment. [9]However, some studies have reported potential side effects of laxatives such as lactulose, including diarrhoea, nausea and bloating. Diarrhoea and vomiting can lead to electrolyte disturbances and even exacerbate HE.[8]</p>
-                 <p>2.Anti-microbial agents:Rifaximin is a semi-synthetic non-aminoglycoside drug that fights Gram-positive, Gram-negative, aerobic and anaerobic enteric bacteria. The strongest evidence for the utility of rifaximin is the use of the drug as an add-on to lactulose for the prevention of hepatic encephalopathy recurrence. [10]However, clinical trials of rifaximin in combination with lactulose have rarely been reported and lack wide public acceptance.</p>
-                 <p>3.Probiotics:Probiotics are live bacteria that are thought to improve intestinal ecological dysbiosis, help enhance ammonia metabolism, and reduce the burden of ammonia on the gut. However, to date, the quality of most clinical trials has been low, so the evidence remains unconvincing. [11]</p>
-                 <p>4.Albumin and extracorporeal albumin dialysis (ECAD):The quantity and quality of albumin, a multifunctional protein synthesised in the liver, is significantly reduced in patients with cirrhosis. An early uncontrolled, non-randomised study suggested its potential role in the treatment of hepatic encephalopathy. [12] However, it was not confirmed in randomised controlled clinical trials.</p>
-                 <p>5.L-Mentholated Ornithine (LOLA).A preliminary meta-analysis of eight randomised controlled trials comparing LOLA with placebo/no intervention control showed that intravenous LOLA improved significant hepatic atherosclerosis. [13] However, the effectiveness of oral LOLA has been the subject of debate, as the AASLD-EASL clinical guidelines suggest that oral supplementation with LOLA is ineffective. [1] Therefore, the potential benefits of LOLA remain uncertain.</p>
+                 <p className="bold-font">1.Osmotic laxatives:</p>
+                 <p>Non-absorbable disaccharides, lactulose and sugar alcohols, are recommended as first-line treatment for HE. Lactulose is a laxative that has a negligible effect on the composition or function of the gut microbiota and may reduce ammonia production and absorption in the gut and increase intestinal excretion by increasing intestinal transport as well as acidification of the intestinal environment. [9]However, some studies have reported potential side effects of laxatives such as lactulose, including diarrhoea, nausea and bloating. Diarrhoea and vomiting can lead to electrolyte disturbances and even exacerbate HE.[8]</p>
+                 <p className="bold-font">2.Anti-microbial agents:</p>
+                 <p>Rifaximin is a semi-synthetic non-aminoglycoside drug that fights Gram-positive, Gram-negative, aerobic and anaerobic enteric bacteria. The strongest evidence for the utility of rifaximin is the use of the drug as an add-on to lactulose for the prevention of hepatic encephalopathy recurrence. [10]However, clinical trials of rifaximin in combination with lactulose have rarely been reported and lack wide public acceptance.</p>
+                 <p className="bold-font">3.Probiotics:</p>
+                 <p>Probiotics are live bacteria that are thought to improve intestinal ecological dysbiosis, help enhance ammonia metabolism, and reduce the burden of ammonia on the gut. However, to date, the quality of most clinical trials has been low, so the evidence remains unconvincing. [11]</p>
+                 <p className="bold-font">4.Albumin and extracorporeal albumin dialysis (ECAD):</p>
+                 <p>The quantity and quality of albumin, a multifunctional protein synthesised in the liver, is significantly reduced in patients with cirrhosis. An early uncontrolled, non-randomised study suggested its potential role in the treatment of hepatic encephalopathy. [12] However, it was not confirmed in randomised controlled clinical trials.</p>
+                 <p className="bold-font">5.L-Mentholated Ornithine (LOLA):</p>
+                 <p>A preliminary meta-analysis of eight randomised controlled trials comparing LOLA with placebo/no intervention control showed that intravenous LOLA improved significant hepatic atherosclerosis. [13] However, the effectiveness of oral LOLA has been the subject of debate, as the AASLD-EASL clinical guidelines suggest that oral supplementation with LOLA is ineffective. [1] Therefore, the potential benefits of LOLA remain uncertain.</p>
                  <p>In conclusion, there is great uncertainty and instability in the treatment of HE, and it is urgent to find more effective and safe treatment options in order to reduce the suffering of patients and the burden on the social healthcare system.</p>
                  <h3>New treatments</h3>
                  <p>We recognise the potential advantage of synthetic biology in solving global health problems by enabling the tight integration of dispersed functional modules. As a result, we plan to take a new angle - sensing phenylethylamine - to stimulate the expression of downstream metabolic modules to degrade excess ammonia in the patient's body, thereby undoing the toxic effects of ammonia overload on the brain. At the same time, our safety module operates at all times to reduce the level of intestinal inflammatory factors and maintain the stability of the intestinal barrier, ensuring the normal state of the metabolic and sensing modules.</p>